Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 7/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21950768 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL22388723 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL21950769 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL24414066 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL24965903 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL24965995 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL24828833 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL24414034 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL21895947 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 | |
| SCHEMBL25658437 | 1.00 | MDM4 (0.38) | MDM4TP53CCR1MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20200277327-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CCR1 1767/4885 |
| US-20200277327-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CCR1 3629/4885 |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CCR1 3629/4885 |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CCR1 3629/4885 |
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CCR1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.